Suvax™ and marvax™ thermostable vaccine platform to be presented at the vaccine technology ix conference

Princeton, n.j. , may 21, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that professor axel lehrer, university of hawaiʽi at mĀnoa (uhm), will be presenting key data from the company's thermostable vaccine technology platform developed in collaboration with uhm, including results from the filovirus vaccine candidates for both sudan ebolavirus (suvax™) and marburg marburgvirus (marvax™).
SNGX Ratings Summary
SNGX Quant Ranking